-
-
-
Loading
Loading
A scrapped $2.5bn share offering is the first victim of a short-seller’s attack
Chris Pappas is an unlikely but effective trailblazer
Monitoring human-rights and environmental standards across their suppliers could have perverse consequences
Can the world’s pharmacy escape a reputation for poor quality control?